CS
CSL Limited
CSL.AX·ASXMelbourne AUFounded 191632,000 employees
Large CapbiotechPublicHematologyImmunologyRare Disease
Platform: Plasma & Recom
Market Cap
$100B
All Drugs
14
Clinical Trials
19
Failed / Terminated
8
FDA Approved
1
Stock Price & Catalysts (CSL.AX)
Loading CSL.AX stock data...
Drug Pipeline (14 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| CSL-2468 | CSL-2468 | Phase 1/2 | 2 | LAG-3 | HNSCCPAH | ||
| CSL-5840 | CSL-5840 | Phase 3 | 1 | GPRC5D | Celiac | ||
| Riboderotide | CSL-6866 | Phase 2 | 1 | PSMA | ASPompe | ||
| CSL-4826 | CSL-4826 | NDA/BLA | 1 | WRN | RCCParkinson's | ||
| Zoricapivasertib | CSL-9759 | Phase 2 | 1 | HER2 | ALLEoE | ||
| Mavulucimab | CSL-6052 | NDA/BLA | 1 | AHR | PompeThymoma | ||
| CSL-8235 | CSL-8235 | Phase 1/2 | 2 | IL-17A | Atopic DermFL | ||
| CSL-8153 | CSL-8153 | Approved | 2 | CD3 | Wet AMDSLE | ||
| Voxafotisoran | CSL-6575 | Phase 1 | 1 | CDK2 | RBWilms | ||
| CSL-5084 | CSL-5084 | NDA/BLA | 1 | PI3Kα | Urothelial Ca | ||
| CSL-4765 | CSL-4765 | Phase 1/2 | 2 | FcRn | LN | ||
| CSL-4459 | CSL-4459 | NDA/BLA | 1 | KRASG12D | MSGBM | ||
| CSL-7919 | CSL-7919 | Preclinical | 2 | BTK | Endometrial CaHemophilia A | ||
| CSL-652 | CSL-652 | Preclinical | 1 | PSMA | CTCL |
SEC Filings & Financial Documents
SEC filings are not available for ASX-listed companies.
CSL Limited trades on ASX (AU). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (17)